{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:25:47Z","timestamp":1781151947296,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ejpb.2023.06.014","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:22:36Z","timestamp":1687623756000},"page":"233-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Topical ocular protein delivery based on protein powder suspensions in semifluorinated alkanes"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0411-1512","authenticated-orcid":false,"given":"Christoph","family":"Marschall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Filster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Hauptmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Frie\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2023.06.014_b0005","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1016\/j.xphs.2017.05.030","article-title":"Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins","volume":"106","author":"Hamuro","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0010","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: How do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.ejpb.2023.06.014_b0015","doi-asserted-by":"crossref","first-page":"e0181748","DOI":"10.1371\/journal.pone.0181748","article-title":"THPdb: Database of FDA-approved peptide and protein therapeutics","volume":"12","author":"Usmani","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2023.06.014_b0020","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1742-481X.2006.00233.x","article-title":"Topical application of the tumour necrosis factor-\u03b1 antibody infliximab improves healing of chronic wounds","volume":"3","author":"Streit","year":"2006","journal-title":"Int. Wound J."},{"issue":"2","key":"10.1016\/j.ejpb.2023.06.014_b0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":"Bevacizumab (Avastin) eye drops inhibit corneal neovascularization","volume":"246","author":"Bock","year":"2008","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.06.014_b0030","first-page":"1063","article-title":"Nerve growth factor promotes corneal healing: Structural, biochemical, and molecular analyses of rat and human corneas","volume":"41","author":"Lambiase","year":"2000","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0035","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM199804233381702","article-title":"Topical Treatment with Nerve Growth Factor for Corneal Neurotrophic Ulcers","volume":"338","author":"Lambiase","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejpb.2023.06.014_b0040","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1167\/iovs.12-10782","article-title":"Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring","volume":"54","author":"Ferrari","year":"2013","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.014_b0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.9.11.15","article-title":"VEGF TrapR1R2 Suspended in the Semifluorinated Alkane F6H8 Inhibits Inflammatory Corneal Hem- and Lymphangiogenesis","volume":"9","author":"Le","year":"2020","journal-title":"Transl. Vis. Sci. Technol."},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.014_b0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0161-6420(99)90009-X","article-title":"Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia","volume":"106","author":"Vann","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ejpb.2023.06.014_b0055","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0002-9394(14)78303-5","article-title":"Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir","volume":"95","author":"Colin","year":"1983","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.06.014_b0060","unstructured":"ANNEX I - SUMMARY OF PRODUCT CHARACTERISTICS for Oxervate, https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170706138232\/anx_138232_en.pdf, accessed on Dec 14th 2018."},{"key":"10.1016\/j.ejpb.2023.06.014_b0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular Drug Delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2023.06.014_b0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0168-3659(97)00078-3","article-title":"Estimation of pore size and pore density of biomembranes from permeability measurements of polyethylene glycols using an effusion-like approach","volume":"49","author":"Mari H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2023.06.014_b0075","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/jps.24465","article-title":"Permeation of Proteins, Oligonucleotide and Dextrans Across Ocular Tissues: Experimental Studies and a Literature Update","volume":"104","author":"Pescina","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0080","unstructured":"B. Guenther, et al. EP2806886B1 - Stabilised protein compositions based on semifluorinated alkanes. (2013)."},{"key":"10.1016\/j.ejpb.2023.06.014_b0085","unstructured":"G. Graf, B. Guenther, D. Scherer, A. Pettigrew, EP3024484A1 - Stabilized antibody compositions. (2016)."},{"key":"10.1016\/j.ejpb.2023.06.014_b0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejpb.2014.05.009","article-title":"Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery","volume":"88","author":"Dutescu","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2023.06.014_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2018.01.019","article-title":"Semifluorinated alkane based systems for enhanced corneal penetration of poorly soluble drugs","volume":"538","author":"Agarwal","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.06.014_b0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/112067210001000301","article-title":"Semifluorinated alkanes - A new class of compounds with outstanding properties for use in ophthalmology","volume":"10","author":"Meinert","year":"2000","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.ejpb.2023.06.014_b0105","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejpb.2021.01.014","article-title":"Powder suspensions in non-aqueous vehicles for delivery of therapeutic proteins","volume":"161","author":"Marschall","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"8","key":"10.1016\/j.ejpb.2023.06.014_b0110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/sj.eye.6701669","article-title":"Topically applied antibody fragments penetrate into the back of the rabbit eye","volume":"19","author":"Williams","year":"2005","journal-title":"Eye"},{"key":"10.1016\/j.ejpb.2023.06.014_b0115","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2249.2002.01808.x","article-title":"Penetration of engineered antibody fragments into the eye","volume":"128","author":"Thiel","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejpb.2023.06.014_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijpharm.2014.06.007","article-title":"Enhancement in corneal permeability of riboflavin using calcium sequestering compounds","volume":"472","author":"Morrison","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2023.06.014_b0125","article-title":"Temperature-Induced Unfolding, Aggregation, and Interaction of Therapeutic Monoclonal Antibodies","author":"Menzen","year":"2014","journal-title":"(LMU Munich"},{"key":"10.1016\/j.ejpb.2023.06.014_b0130","article-title":"Stabilization of Antibodies in Spray-dried Powders for Inhalation","author":"Schuele","year":"2005","journal-title":"(LMU Munich"},{"issue":"10","key":"10.1016\/j.ejpb.2023.06.014_b0135","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin\u00ae) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ejpb.2023.06.014_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.xphs.2022.06.016","article-title":"Drug Product Characterization of High Concentration Non-Aqueous Protein Powder Suspensions","volume":"112","author":"Marschall","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0145","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11095-012-0854-x","article-title":"The Role of Polysorbate 80 and HP\u03b2CD at the Air-Water Interface of IgG Solutions","volume":"30","author":"Serno","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.06.014_b0150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/js970308x","article-title":"Spray-Drying of Air-Liquid Interface Sensitive Recombinant Human Growth Hormone","volume":"87","author":"Maa","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbapap.2005.06.005","article-title":"How to study proteins by circular dichroism","volume":"1751","author":"Kelly","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejpb.2023.06.014_b0160","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ejps.2009.06.001","article-title":"Structural properties of monoclonal antibody aggregates induced by freeze \u2013 thawing and thermal stress","volume":"38","author":"Hawe","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0165","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1023\/A:1011994514358","article-title":"Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures","volume":"15","author":"Knepp","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2023.06.014_b0170","unstructured":"Weiguo Dai, Beth Hill, Kui Liu, C. M. US 20120076800 - Non-aqueous high concentration reduced viscosity suspension formulations of antibodies. (2012)."},{"key":"10.1016\/j.ejpb.2023.06.014_b0175","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1023\/A:1018823100761","article-title":"Reversible increase in Tight Junction Permeability to Macromolecules in Rat Ileal mucosa In Vitro by Sodium Caprate, a constituent of milk fat","volume":"43","author":"Soederholm","year":"1998","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics15041211","article-title":"Semifluorinated Alkanes as New Drug Carriers\u2014An Overview of Potential Medical and Clinical Applications","volume":"15","author":"Tsagogiorgas","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ejpb.2023.06.014_b0185","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1208\/ps040102","article-title":"Ocular tolerance of absorption enhancers in ophthalmic preparations","volume":"4","author":"Furrer","year":"2002","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ejpb.2023.06.014_b0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1167\/iovs.08-2372","article-title":"Efficient intraocular penetration of topical anti-TNF-\u03b1 single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer","volume":"50","author":"Ottiger","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0195","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1167\/iovs.08-2370","article-title":"Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-\u03b1 single-chain antibody, upon topical administration to the rabbit eye","volume":"50","author":"Furrer","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ejpb.2023.06.014_b0200","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1248\/bpb.30.2360","article-title":"Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients","volume":"30","author":"Nakamura","year":"2007","journal-title":"Biol. Pharm. Bull."},{"issue":"11","key":"10.1016\/j.ejpb.2023.06.014_b0205","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1039\/C8LC00158H","article-title":"A microengineered human corneal epithelium-on-a-chip for eye drops mass transport evaluation","volume":"18","author":"Bennet","year":"2018","journal-title":"Lab Chip"},{"key":"10.1016\/j.ejpb.2023.06.014_b0210","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.ejpb.2017.03.021","article-title":"DynaMiTES \u2013 A dynamic cell culture platform for in vitro drug testing PART 2 \u2013 Ocular DynaMiTES for drug absorption studies of the anterior eye","volume":"126","author":"Bei\u03b2ner","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641123001674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:53:56Z","timestamp":1760547236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641123001674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":42,"alternative-id":["S0939641123001674"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.014","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical ocular protein delivery based on protein powder suspensions in semifluorinated alkanes","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2023.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}